Summary of Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Ratings on Dec 8, 2018

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Corporate Logo

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Ratings Coverage

Total analysts of 3 have positions in Fresenius Medical Care (NYSE:FMS) as follows: 2 rated it a “Buy”, 0 with “Sell” and 1 with “Hold”. The positive are 67%. Since August 28, 2018 according to StockzIntelligence Inc Fresenius Medical Care has 3 analyst reports. On Tuesday, August 28 HSBC upgraded the shares of FMS in report to “Buy” rating. In Friday, October 26 report UBS upgraded the stock to “Buy” rating. On Thursday, October 18 DZ Bank downgraded Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) to “Hold” rating. Listed here are Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) PTs and latest ratings.

26/10/2018 Broker: UBS Old Rating: Neutral New Rating: Buy Upgrade
18/10/2018 Broker: DZ Bank Old Rating: Buy New Rating: Hold Downgrade
28/08/2018 Broker: HSBC Old Rating: Hold New Rating: Buy Upgrade

The stock decreased 9.07% or $3.56 during the last trading session, touching $35.67.Fresenius Medical Care AG & Co. KGaA is uptrending after having risen 4.38% since December 8, 2017. FMS has 749,471 volume or 208.65% up from normal. FMS underperformed the S&P500 by 11.24%.

Fresenius Medical Care AG & Co. KGaA, a kidney dialysis company, provides dialysis care and related services, and other health care services.The firm is valued at $21.85 billion. It offers dialysis treatment, and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized ESRD patients and for patients suffering from acute kidney failure.The P/E ratio is 9.66. The firm also develops, makes, and distributes dialysis products, including hemodialysis machines, peritoneal cyclers, dialyzers, peritoneal solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, and water treatment systems for the treatment of ESRD; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular, cardiovascular, and endovascular specialty, as well as hospitalist and intensivist, and medical cost management services.

For more Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) news announced recently go to: Nasdaq.com, Seekingalpha.com, Seekingalpha.com, Seekingalpha.com or Seekingalpha.com. The titles are as follows: “Why Cara Therapeutics Is Up 50% in 2018 – Nasdaq” announced on December 02, 2018, “Fresenius Medical Care (FMS) Presents At Citi 2018 European Healthcare Conference – Slideshow – Seeking Alpha” on June 21, 2018, “Merger Arbitrage Opportunity In NxStage Medical – $30 Cash Offer From Fresenius – Seeking Alpha” with a publish date: February 08, 2018, “Fresenius Medical Care AG & Co. KGAA 2018 Q2 – Results – Earnings Call Slides – Seeking Alpha” and the last “Raytheon: Hit Hard By Defense Sell-Off, Patience Will Reward Shareholders – Seeking Alpha” with publication date: November 23, 2018.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.